Recruiting

Calcium Gluconate for Reduced Blood Loss During Vaginal Delivery

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to prevent excessive blood loss during vaginal delivery by using Calcium Gluconate, measuring its effectiveness by the proportion of participants with a decrease of at least 2 g/dL in hemoglobin concentration and the mean change in hemoglobin levels from pre-delivery to the lowest postpartum level recorded during hospitalization.

What is being tested

calcium gluconate

+ Normal saline placebo

Drug
Who is being recruted

Urogenital Diseases+9

+ Dystocia

+ Female Urogenital Diseases and Pregnancy Complications

Over 18 Years
+7 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Placebo-Controlled
Interventional
Study Start: June 2026
See protocol details

Summary

Principal SponsorRambam Health Care Campus
Study ContactGili Buchnik Fater, MDMore contacts
Last updated: July 20, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 24, 2026

Actual date on which the first participant was enrolled.

Postpartum hemorrhage (PPH) remains a major cause of maternal morbidity worldwide. In addition to clinically recognized PPH, a substantial proportion of women experience significant postpartum hemoglobin decline without overt signs of excessive bleeding. Such blood loss may contribute to postpartum anemia, fatigue, delayed recovery, and increased healthcare utilization. Calcium plays a critical role in both uterine muscle contraction and the coagulation cascade. Transient reductions in serum calcium concentrations have been observed during labor and immediately after delivery. It has been hypothesized that calcium supplementation during the third stage of labor may enhance uterine contractility and reduce postpartum blood loss. The objective of this randomized, double-blind, placebo-controlled trial is to evaluate whether intravenous calcium gluconate administered immediately after umbilical cord clamping reduces postpartum blood loss following vaginal delivery. Eligible participants will be randomized in a 1:1 ratio to receive either 10 mL of 10% calcium gluconate diluted in 100 mL of normal saline or 110 mL of normal saline placebo administered intravenously immediately after umbilical cord clamping. Participants, healthcare providers, and outcome assessors will remain blinded to treatment allocation. The co-primary outcomes are: (1) the proportion of participants experiencing a hemoglobin decrease of at least 2 g/dL from the pre-delivery value to the lowest postpartum hemoglobin value recorded during hospitalization, and (2) the mean change in hemoglobin level from the pre-delivery value to the lowest postpartum hemoglobin value recorded during hospitalization. Secondary outcomes include clinically diagnosed postpartum hemorrhage, need for additional uterotonic medications, blood transfusion, intravenous iron administration, length of hospital stay, and composite maternal morbidity outcomes. The findings of this study may provide evidence regarding the effectiveness and safety of calcium gluconate as a simple and inexpensive intervention for reducing postpartum blood loss after vaginal delivery.

Principal SponsorRambam Health Care Campus
Study ContactGili Buchnik Fater, MDMore contacts
Last updated: July 20, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

710 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Male

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesDystociaFemale Urogenital Diseases and Pregnancy ComplicationsHemorrhageObstetric Labor ComplicationsPathologic ProcessesPregnancy ComplicationsPuerperal DisordersPathological Conditions, Signs and SymptomsUterine HemorrhagePostpartum HemorrhageUterine Inertia

Criteria

1 inclusion criteria required to participate
Gestational age of 37 weeks or more, and planning a vaginal delivery

6 exclusion criteria prevent from participating
Patients treated with calcium channel blockers

Patients with known Para-Thyroid disease

Age younger than 18 years old

Sarcoidosis

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Participants will receive 10 mL of 10% calcium gluconate solution (0.94 g calcium gluconate) diluted in 100 mL normal saline administered intravenously immediately following umbilical cord clamping during the third stage of labor.

Group II

Placebo
Participants will receive 110 mL of 0.9% normal saline administered intravenously immediately following umbilical cord clamping during the third stage of labor.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Rambam Medical Center

Haifa, IsraelOpen Rambam Medical Center in Google Maps
Recruiting
One Study Center